Takeda Pharmaceutical Company Limited (TAK)

13,28 -0,08 (-0,60%) Al cierre: 04:00PM EDT

Takeda Pharmaceutical Company Limited

1-1, Nihonbashi-Honcho 2-chome
Chuo-ku
Tokyo 103-8668
Japan
81 3 3278 2111
https://www.takeda.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 49.095

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Christophe Weber	President, CEO & Representative Director	3,71M	N/A	1966
Dr. Andrew S. Plump	President of Research & Development and Representative Director	2,65M	N/A	1965
Dr. Seigo Izumo	Chair of Management Board	N/A	N/A	N/A
Mr. Milano Furuta	Chief Financial Officer	N/A	N/A	1978
Mr. Haruhiko Hirate	Member of Management Board	N/A	N/A	1957
Mr. Salvatore Alesci M.D., Ph.D.	Member of Management Board and Head of R&D Global Science & Biomedical Policy	N/A	N/A	1975
Norimasa Takeda	Chief Accounting Officer & Corporate Controller	N/A	N/A	N/A
Mr. Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department	N/A	N/A	N/A
Mr. Gabriele Ricci	Chief Data & Technology Officer	N/A	N/A	1978
Mr. Christopher David O'Reilly	Global Head of Investor Relations & Global Finance	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Gobierno corporativo

El ISS Governance QualityScore de Takeda Pharmaceutical Company Limited, a día 1 de mayo de 2024, es 1. Las puntuaciones base son Auditoría: 1; Tablero: 1; Derechos de los accionistas: 5; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.